Background: Pulmonary vein isolation (PVI) is a foundational treatment for persistent atrial fibrillation (PeAF), but the effectiveness of adding posterior wall isolation (PWI) and selective complex fractionated atrial electrogram (CFAE) ablation in the roof and anterior wall remains debated. The potential of these additional ablation techniques to improve long-term outcomes for PeAF patients is still uncertain. Methods: This retrospective study included 151 PeAF patients who underwent first-time catheter ablation at our center. The choice of ablation strategy was based on the operator’s clinical judgment, taking into account the patient’s specific condition and anatomical features. Patients were divided into two groups: the PVI group, which received PVI alone, and the modified PWI (MPWI) group, which received PVI along with additional PWI and selective CFAEs ablation in the roof and anterior wall. The primary endpoint was the absence of atrial arrhythmia lasting more than 30 s, without antiarrhythmic drugs, at 12 months. Results: At the 12-month follow-up, 77.3% of the patients in the MPWI group and 52.1% of the patients in the PVI group remained in sinus rhythm without an atrial arrhythmia recurrence (p = 0.001). The BIC-based Cox regression analysis identified the ablation strategy and atrial fibrillation (AF) duration as independent predictors of recurrence across the cohort. It was found that MPWI significantly reduced the risk of recurrence, while a longer AF duration increased it. In the MPWI group, AF duration, left ventricular internal diameter in systole (LVIDs), and moderate or greater tricuspid regurgitation were independent predictors of recurrence. In the PVI group, only the left atrial low voltage area (LVA) index was a significant predictor. Conclusion: The addition of PWI and selective CFAE ablation to PVI significantly improves 12-month arrhythmia-free survival compared to PVI alone, demonstrating the superiority of this combined approach in improving long-term outcomes for patients with persistent AF.
Background: Intracardiac echocardiography (ICE)-guided percutaneous endocardial septal ablation (PESA) is a promising alternative strategy for symptomatic hypertrophic obstructive cardiomyopathy (HOCM). However, the extent of left ventricular outflow tract gradient (LVOTG) reduction after PESA varies considerably among patients, and reliable echocardiographic predictors of procedural efficacy remain unclear. We aimed to identify echocardiographic predictors of procedural efficacy and to describe our ablation strategy. Methods: We retrospectively analyzed 30 consecutive symptomatic HOCM patients who underwent ICE-guided PESA. The primary endpoint was the absolute change in resting LVOTG from baseline to the 1-year follow-up; a key secondary endpoint was significant gradient reduction, defined as a ≥50% decrease in resting LVOTG. Associations between LVOTG reduction and baseline echocardiographic parameters, particularly anterior mitral leaflet length (AMLL) and interventricular septal thickness (IVST), were evaluated. Results: At 1 year, the mean resting LVOTG decreased from 86.03 ± 24.30 mmHg to 41.43 ± 18.49 mmHg (p < 0.001). For the key secondary endpoint (≥50% resting LVOTG reduction), AMLL was the only variable associated with the outcome in the prespecified multivariable logistic model (OR per 1 mm increase: 0.429; p = 0.006), with consistent findings in a Firth penalized logistic regression sensitivity analysis. ROC analysis identified an exploratory AMLL cutoff of approximately 29 mm (AUC 0.920; sensitivity 90%; specificity 80%). In the continuous-outcome analysis, each 1 mm increase in AMLL corresponded to approximately 4.3 mmHg less LVOTG reduction (β = −4.32; p < 0.001). Thinner IVST was not significantly associated with greater procedural efficacy (p = 0.052), suggesting a potential thickness-dependent limit that warrants further investigation. Conclusions: ICE-guided PESA effectively reduces LVOT obstruction in HOCM. Shorter AMLL predicted greater LVOT gradient reduction in this exploratory cohort, and a Youden-derived AMLL cutoff of approximately 29 mm may help identify patients who are more likely to achieve substantial gradient reduction.